Last reviewed · How we verify

Unresectable advanced or recurrent esophageal cancer — Treatment Landscape & Competitive Intelligence

Unresectable advanced or recurrent esophageal cancer (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Unresectable advanced or recurrent esophageal cancer, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Yervoy Yervoy Bristol-Myers Squibb Cytotoxic T-lymphocyte protein 4
Yervoy ipilimumab Bristol-Myers Squibb CTLA-4-directed Blocking Antibody Cytotoxic T-lymphocyte protein 4 2011-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bristol-Myers Squibb · 2 drugs in Unresectable advanced or recurrent esophageal cancer

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Unresectable advanced or recurrent esophageal cancer:

Cite this brief

Drug Landscape (2026). Unresectable advanced or recurrent esophageal cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-advanced-or-recurrent-esophageal-cancer. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing